Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank
July 07, 2021 08:05 ET
|
Impel NeuroPharma
SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for...
Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference
June 16, 2021 08:00 ET
|
Impel NeuroPharma
SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living...
Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update
June 07, 2021 08:05 ET
|
Impel NeuroPharma
– Completed successful IPO raising approximately $80.0 million in gross proceeds –– NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6,...
Impel Neuropharma to Present Pivotal, Phase 3 Data From STOP-301 Study at The 63rd Annual Meeting of the American Headache Society
June 02, 2021 08:00 ET
|
Impel NeuroPharma
Data Will Evaluate Exploratory Efficacy Data from STOP-301 Study Evaluating INP104 Consistency of Response, Recurrence and Sustained Response Findings Also Highlight Safety and Tolerability Including...
Impel NeuroPharma Launches Reroute Migraine Relief, Educational Initiative That Brings to Life the Underrecognized Connection Between Migraine, the Brain and Gut
May 18, 2021 08:00 ET
|
Impel NeuroPharma
SEATTLE, May 18, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical company, today launched Reroute Migraine Relief, an educational initiative which aims to...
Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering
April 22, 2021 18:48 ET
|
Impel NeuroPharma
SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize...